雲
01952
雲頂新耀
23.800
-5.480-18.72%Closed16:08 08/19 HKT
OPEN/PREV CLOSE27.360/23.800
TODAY RANGE27.360-45.040
VOL115.88M
MARKET CAP11.91B
52 WEEK RANGE22.700-75.150
AVG VOL (3M)5.33M
% TURNOVER32.75%
TURNOVER4.27B
P/E (TTM)-191.904
% RANGE74.29%
EPS(TTM)-0.175
P/E(FORWARD)70.536
P/B1.978
BVPS17.015
DIVIDEND--
P/S4.295
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP11.91B
SHARES OUTSTANDING353.84M
NEXT EARNINGS--
FREE FLOAT353.84M
LOT SIZE500
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·20h ago
Everest Medicines (SEHK:1952) Stock Can Revenue Scale Turn Near Profit Durable
Simply Wall St·1d ago
Should Everest Medicines’ (SEHK:1952) Surging Revenue and Near Break-Even Results Prompt Investor Action?
Simply Wall St·08/08 00:43
We Might See A Profit From Everest Medicines Limited (HKG:1952) Soon
Simply Wall St·06/15 05:14
Everest Medicines (SEHK:1952) Stock Valuation After New Ophthalmology And Cardiovascular Licensing Deals
Simply Wall St·06/12 09:35
Everest Medicines Expands Partnerships To Broaden Pipeline And Future Cash Flows
Simply Wall St·06/06 08:10
Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Weakness
Simply Wall St·05/28 05:23
Everest Medicines Insiders Placed Bullish Bets Worth CN¥98.2m
Simply Wall St·03/30 01:06
Everest Medicines (SEHK:1952) Is Up 15.7% After Revenue Surges And Loss Narrows In 2025 Results - Has The Bull Case Changed?
Simply Wall St·03/27 11:20
Everest Medicines (SEHK:1952) Loss Narrows To C¥249.8m Challenging Bearish Narratives
Simply Wall St·03/21 01:11
A Look At Everest Medicines (SEHK:1952) Valuation After Recent Share Price Pullback
Simply Wall St·02/14 03:29
Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Volatility
Simply Wall St·02/05 19:38
Everest Medicines MT1013 Deal Expands Renal Pipeline As Shares Lag Targets
Simply Wall St·01/21 23:34
Revenues Not Telling The Story For Everest Medicines Limited (HKG:1952)
Simply Wall St·12/16/2025 10:19
Do Everest Medicines’ 2030 Plan And Insider Buying Reframe Its Risk-Reward Profile (SEHK:1952)?
Simply Wall St·12/14/2025 21:22
Everest Medicines (SEHK:1952): Revisiting Valuation After Recent Share Price Weakness
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.